» Articles » PMID: 36974778

Cut-off Analysis of HLA-A and HLA-B/C Expression As a Potential Prognosticator of Favorable Survival in Patients With Metastatic Breast Cancer

Overview
Journal Anticancer Res
Specialty Oncology
Date 2023 Mar 28
PMID 36974778
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aim: Loss of differentiation of breast cancer cells in association with a down-regulated class I human leukocyte antigen (HLA) expression can lead to proliferation unhampered by cytotoxic T lymphocytes, which has been proven to be of prognostic relevance. The objective of this study was to determine the levels of HLA-A and HLA-B/C expression in metastatic breast cancer (MBC) cells and their usefulness for predicting 5-year survival.

Materials And Methods: This prospective double-blinded cohort study analyzed patients starting a new line of therapy for MBC. RT-qPCR was used to determine the levels of HLA-A and B/C expression in MBC cells and the mRNA-based tumor intrinsic subtype. Two receiver operating characteristic curves (ROC) were constructed in order to determine whether HLA-A and HLA-B/C expression levels can be used for predicting 5-year survival. Youden J points, and sensitivity and specificity optimized cut-off points were determined for both ROC curves.

Results: We enrolled 34 patients. The ROC curve for HLA-B/C had the highest AUC compared to HLA-A (0.55 vs. 0.42). High levels of HLA-A and HLA-B/C expression (40-ΔΔCT of 33.5 and 31.9, respectively) were highly specific (reaching 87.5% for HLA-A and even 100% specificity for HLA-B/C) yet insensitive for five-year survival in our study.

Conclusion: High expression of certain class I HLA molecule subtypes by MBCs, in particular high HLA-A or B/C expression by MBC cells seems very specific in predicting the 5-year survival. We determined cut-off values for these HLA molecule clusters with high specificity, which might help identify patients with a favorable prognosis as prognosticators of a 5-year overall survival if their sensitivity is improved in larger prospective cohorts.

Citing Articles

Correlation of HLA-A and HLA-B/C Expression With PD-1 and PD-L1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable Survival.

Goerdt L, Stefanovic A, Wirtz R, Karic U, Kohler M, Deutsch T In Vivo. 2025; 39(2):758-765.

PMID: 40010968 PMC: 11884484. DOI: 10.21873/invivo.13880.


Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities.

Garrido M, Navarro-Ocon A, Ronco-Diaz V, Olea N, Aptsiauri N Genes (Basel). 2025; 15(12.

PMID: 39766811 PMC: 11675875. DOI: 10.3390/genes15121542.


Breast cancer, viruses, and human leukocyte antigen (HLA).

James L, Georgopoulos A Sci Rep. 2024; 14(1):16179.

PMID: 39003313 PMC: 11246526. DOI: 10.1038/s41598-024-65707-9.


Antiproliferative and Apoptotic Effects of Tempol, Methotrexate, and Their Combinations on the MCF7 Breast Cancer Cell Line.

Kaplan H, Pazarci P ACS Omega. 2024; 9(6):6658-6662.

PMID: 38371775 PMC: 10870381. DOI: 10.1021/acsomega.3c07624.